Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
Revenue Growth %: +36.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +36.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $31.9 million versus the consensus estimate of $33.86 million.
GUIDANCE:
Halozyme Therapeutics sees 2016 revenue of $145-150 million, versus the consensus of $146.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
